ArticleDiscover oncology2025
PLAUR, C3, and EMP3 coordinate tumor progression and immune evasion in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) progression is closely associated with the tumor microenvironment and immune evasion mechanisms. Identifying key molecular drivers is critical for advancing ccRCC diagnosis and therapy.
methodsDifferentially expressed genes (DEGs) were identified through analysis of the GSE6344 and GSE781 datasets. Weighted Gene Co-expression Network Analysis (WGCNA) was performed to uncover co-expression modules that exhibit significant correlation with clinical traits. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, coupled with survival analysis, were employed to pinpoint potential hub genes. Single-cell RNA-seq data were analyzed to clarify cellular sources of PLAUR, C3, and EMP3. Functional validation of these genes was conducted using a range of assays, including RT-qPCR, Western blotting, CCK-8, wound healing, Transwell, and ELISA in both normal kidney cells and ccRCC cell lines.
resultsPLAUR, C3, and EMP3 were identified as hub genes enriched in extracellular matrix and immune-related pathways. All three genes were found to be overexpressed in ccRCC and associated with poor prognosis. Single-cell RNA-seq analysis revealed that PLAUR and C3 are primarily expressed in immune cells with detectable levels in tumor epithelial cells, whereas EMP3 exhibits a broader distribution, including strong expression in tumor epithelial cells. Silencing of PLAUR, C3, or EMP3 resulted in a marked inhibition of tumor proliferation, migration, and invasion. Notably, PLAUR knockdown exhibited the most substantial effect, disrupting immune evasion by reducing the levels of TGF-β, IL-10, and IL-6, while increasing the levels of IFN-γ, IL-2, and TNF-α in ccRCC cells co-cultured with T-cells.
conclusionsPLAUR, C3, and EMP3 promote ccRCC progression and immune evasion, with PLAUR acting as the dominant driver. Targeting PLAUR may provide a promising strategy to enhance anti-tumor immunity in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.